Vectus Biosystems Limited · ASX:VBS
Vectus Biosystems — Shareholder Meeting (November 2024)
27 slides from Vectus Biosystems's shareholder meeting presentation, Nov 27, 2024
Slide 1: Chairman's Address to the 27 November 2024 AGM
ABN 54 117 526 137 Vectus Biosystems Limited Chairman’s Address to the 27 November 2024 Annual General Meeting On 24 May 2024 Vectus sadly reported the passing of its co-founder and Chief Executive Officer, Dr Karen Duggan, who, for 18 years, led the Company in an attempt to meet the challenge of pr
Slide 2: Chairman's Address (continued): Accugen and Conclusion
ABN 54 117 526 137 pleased to report that engagement with well-known pharmaceutical companies has been expanded and today Martina Molsbergen from C14 will be providing some insight into this process. Accugen Accugen is one of Vectus’ assets that will be made available to the industry to commercialis
Slide 3: C14 Consulting Group Company Presentation
For personal use only November 2024 Company Presentation C14 Consulting Group For the Business of Life Sciences www.c14consultingroup.com
Slide 4: Martina Molsbergen, CEO, C14 Consulting Group
Martina Molsbergen CEO, C14 Consulting Group For personal use only +34 years of business development, marketing, and entrepreneurial experience including 24 years of business development experience in biotherapeutics and antibodies Proven corporate development strategy and leadership experience with
Slide 5: Exceptional Knowledge
Exceptional Knowledge Broad access to academia and industry For personal use only Business & Investment Strategy C14 is built on a large pedigree of former industry executives with proven track Deal Making records of success Scientific Evaluation
Slide 6: Pedigree Team & Access to KOLs
Pedigree Team & Access to KOLs For personal use only Large team of execs, scouts, Strong competence and C14 Team offers: heads of R&D, and KOLs technical expertise in protein ✓ High-value ✓ Trained Effective and (MD, Ph.D.) chemistry and drug Reliable with +20 years industry discovery/development ✓
Slide 7: Deal Making Success
Deal Making Success Proven Track Record is Core Competence Plethora of deals spanning discovery, For personal use only clinical and commercial Out licensing focused (“sell” side), negotiations, transactions and strategic alliance management history Leverage C- level contacts within many Affiliated w
Slide 8: Large Experience Base
Large Experience Base For personal use only Life Science Sectors Therapeutic Areas Geographic Pharmaceuticals Cardiology Experience CNS Diagnostics Dermatology North America Immunology Immunology South America Biologics Infectious Disease Europe Vaccines Oncology Pain & Inflammatory Disease Asia Pla
Slide 9: Strategy Refinement
Strategy Refinement For personal use only Work with clients to develop a blueprint strategy for optimally positioning & maximizing the value of any deal Evaluate client’s current capabilities and desired goals for future growth; identify competitive strengths, capital needs & exit strategies Special
Slide 10: Business Development Planning
Business Development Planning For personal use only ✓ Determine best selling features for differentiation ✓ Target list of potential clients ✓ Outreach through existing network/ licensing and scientific meetings/ publications/ sponsorships ✓ Competitive intelligence ✓ Drive decision making to result
Slide 11: Generating, Accelerating & Expanding Transactional Opportunities
Generating, Accelerating & Expanding Transactional Opportunities For personal use only ✓ Sourcing, structuring and executing transactional opportunities ✓ Creating optimal deal structures: Licensing, Partnering, M&A ✓ Asset acquisition and divestiture ✓ Creating venturing capabilities ✓ Corporate fo
Slide 12: Contact Information
Contact Information: Martina Molsbergen, CEO mmolsbergen@c14consultinggroup.com www.c14consultinggroup.com For personal use only O: (610) 644-2243 M: (610) 291-2726 Thank you!
Slide 13: Appendix
For personal use only Appendix
Slide 14: Representative Clients: Large Clients
Representative Clients Large Clients For personal use only
Slide 15: Representative Clients: Early/Mid stage Clients
Representative Clients Early/Mid stage Clients For personal use only Annakim Biosciences zacharon pharmaceutical s
Slide 16: Representative Clients: Small & Mid Size Biotech/Specialty Pharma
Representative Clients Small & Mid Size Biotech/ Specialty Pharm For personal use only Health Ever Biotech KisoJi
Slide 17: Representative Clients: Gov't & Non-Gov't Organizations
Representative Clients Gov’t & Non-Gov’t Organizations For personal use only
Slide 18: Representative Clients: Investors
Representative Clients Investors For personal use only
Slide 19: Working With Numerous Investors
Working With Numerous Investors • Hercules Technology • A.M. Pappas & Associate • Paramount BioCapital • Horizon Technology • ABV • Paul Capital Partners For personal use only Finance • Accelerator • Prospect Venture • Innovis • Actin Biomed Partners • J & J Ventures (JJDC) • Aisling Capital • Puret
Slide 20: Existing Network Of World Class Institutions & Partners
Existing Network Of World Class Institutions & Partners For personal use only Institutions & Government Organizations:
Slide 21: Recognized Abilities
Recognized Abilities For personal use only ✓ Nikkei article 2012 ✓ Recipient of 2 President’s Awards, Kyowa Hakko Kogyo 2005, 2007 ✓ Nikkei article May 2007 ✓ BioCentury, “Cracking the Code” April 23, 2012 Vol 20, Number 17, pp A1 of 18.
Slide 22: Solutions for Unmet Medical Needs (Extracts)
Corporate Presentation For personal use only (Extracts) Solutions for Unmet Medical Needs
Slide 23: Introducing Vectus Biosystems
Introducing VECTUS BIOSYSTEMS For personal use only Advanced Novel Peptide Therapeutic Treatments for Diseases with High Unmet Needs Publicly traded ASX:VBS Company Highlights • Robust clinical pipeline of fibrosis treatments for high unmet needs • Accugen Technology: Next generation discovery engin
Slide 24: Robust VIP Pipeline
Robust VIP Pipeline Preclinical IND Phase 1 Phase 2 For personal use only VB0004 Myocardial & Renal Fibrosis (including TTR-CM/CF) *Orphan Designation VB0004 Pulmonary Fibrosis VB4-A32 Liver Fibrosis Pulmonary Fibrosis, VB4-A79 Blood Pressure VB4-P5 Renal Antifibrotic *Orphan Indication 3
Slide 25: Cardiovascular Diseases Represent the Leading Cause of Death Worldwide
Cardiovascular Diseases Represent For personal use only the Leading Cause of Death Worldwide, Accounting for Nearly 18 Million Deaths Annually The development of myocardial fibrosis associated with all cardiovascular disease, representing pathological changes that correspond with worsened clinical o
Slide 26: Treatment Challenges Present Large Economic Burden
Treatment Challenges Present Large Economic Burden Heart disease remains the predominant cause of mortality in the For personal use only United States, accounting for nearly 800,000 deaths per year. PRESENTS A CONSIDERABLE ECONOMIC BURDEN 2011: Predicted Rising Costs 2030: USD 320 Billion USD 918 Bi
Slide 27: VB0004: Novel, First-In-Class VIP Agonist for Myocardial & Renal Fibrosis
VB0004: Novel, First- In-Class VIP Agonist For personal use only for Treatment of Myocardial & Renal Fibrosis Replenishing VIP in Tissue 6 6
Vectus Biosystems — Shareholder Meeting (November 2024) on 6ix